Dec 12 (Reuters) – Danish drugmaker Novo Nordisk launched its blockbuster diabetes drug Ozempic in India on Friday.
Ozempic, a once-weekly injectable approved by the U.S. Food and Drug Administration in 2017 for type 2 diabetes, has become a global bestseller and is widely used off-label for weight loss due to its appetite-suppressing effects.
(Reporting by Rishika Sadam and Kashish Tandon; Editing by Janane Venkatraman)
